tickdelta
Sign in

Tickdelta is free for now. Sign up and get Pro free

← Screener

VTRVentas

Real estate · REIT · NYSE
Compare with peers → Embed
Planned sales, announced before they happen

1 trading plan running, 21 Form 144 notices for $44.2M

10-Q, 10-K and Form 144
Plans running now
1
Robert F. Probst
Plans adoptedList ↓
6
reported since May 9, 2023
Form 144 noticesList ↓
21
$44.2M the sellers expected to sell

What VTR's directors and officers said they would sell, before they sold: trading plans the company reports each quarter, and the Form 144 notices sellers file on the day of a planned sale. Most of these sales are routine, such as selling shares from vesting stock awards.

Trading plans

Plans adopted or ended

XBRL, 10-Q and 10-K
InsiderWhatDateSharesRuns toReported in
Peter J. Bulgarelli
Executive Vice President, Outpatient Medical and Research
Adopted 10b5-1 plan Feb 20, 2025 up to 15,000 Feb 20, 2026 10-Q May 1, 2025
What the company wrote
On February 20, 2025, Peter J. Bulgarelli, Executive Vice President, Outpatient Medical and Research of the Company and President and CEO of Lillibridge Healthcare Services, Inc., adopted a trading plan intended to satisfy the conditions under Rule 10b5-1(c) of the Exchange Act. Mr. Bulgarelli’s trading plan is for the sale of up to 15,000 shares of our common stock in amounts and prices determined in accordance with a formula set forth in the plan and terminates on the earlier of the date all the shares under the plan are sold and February 20, 2026.
Robert F. Probst
Executive Vice President and Chief Financial Officer
Adopted 10b5-1 plan Feb 19, 2025 up to 320,057 Jan 15, 2027 10-Q May 1, 2025
What the company wrote
On February 19, 2025, Robert F. Probst, Executive Vice President and Chief Financial Officer of the Company, adopted a trading plan intended to satisfy the conditions under Rule 10b5-1(c) of the Exchange Act. Mr. Probst’s trading plan covers (i) the sale of an amount of shares of our common stock necessary to generate an aggregate of up to $4.6 million in net proceeds and (ii) the potential exercise and sale of up to 320,057 shares of our common stock with respect to expiring options, in each case in amounts and prices determined in accordance with a formula set forth in the plan, and terminates on the earlier of the date all the shares under the plan are sold and January 15, 2027.
Walter C. Rakowich
director
Adopted 10b5-1 plan Sep 15, 2024 up to 1,459 Jun 30, 2026 10-Q Oct 31, 2024
Gregory R. Liebbe
Chief Accounting Officer
Adopted 10b5-1 plan Aug 13, 2024 up to 21,114 Aug 10, 2025 10-Q Oct 31, 2024
What the company wrote
On August 13, 2024, Gregory R. Liebbe, Chief Accounting Officer of the Company, adopted a trading plan intended to satisfy the conditions under Rule 10b5-1(c) of the Exchange Act. Mr. Liebbe’s trading plan is with respect to his expiring options and covers the potential exercise and sale of up to 21,114 shares of our common stock in amounts and prices determined in accordance with a formula set forth in the plan and terminates on the earlier of the date all the shares under the plan are sold and August 10, 2025.
Peter J. Bulgarelli
Executive Vice President, Outpatient Medical & Research of the Company and President and CEO of Lillibridge Healthcare Services, Inc
Adopted 10b5-1 plan Mar 11, 2024 up to 22,500 365 days 10-Q May 2, 2024
What the company wrote
On March 11, 2024, Peter J. Bulgarelli, Executive Vice President, Outpatient Medical & Research of the Company and President and CEO of Lillibridge Healthcare Services, Inc., adopted a new trading plan intended to satisfy the conditions under Rule 10b5-1(c) of the Exchange Act. Mr. Bulgarelli’s trading plan is for the sale of up to 22,500 shares of our common stock in amounts and prices determined in accordance with a formula set forth in the plan and terminates on the earlier of the date all the shares under the plan are sold and March 11, 2025.
Debra A. Cafaro
Chairman and CEO of the Company
Adopted 10b5-1 plan – up to 1,546,317 1023 days 10-Q May 2, 2024
What the company wrote
On March 28, 2024, Debra A. Cafaro, Chairman and CEO of the Company, adopted a new trading plan intended to satisfy the conditions under Rule 10b5-1(c) of the Exchange Act. Ms. Cafaro’s trading plan is with respect to her expiring options and covers the potential exercise and sale of up to 1,546,317 shares of our common stock in amounts and prices determined in accordance with a formula set forth in the plan and terminates on the earlier of the date all the shares under the plan are sold and January 15, 2027.

From the XBRL of the company's 10-Qs and 10-Ks (Regulation S-K Item 408, reported since 2023): 15 filings checked since May 9, 2023.

Form 144

Notices of planned sales

Form 144 XML, SEC
FiledSellerSharesValueShares came from10b5-1 planForm 4 sales after
May 14, 2026 Walter C. Rakowich
Director
1,152 $104K RSU grant adopted Sep 15, 2024 1,152 shares from May 14, 2026
Mar 2, 2026 GREGORY LIEBBE
Officer
17,248 $1.5M ESOP none given none found
Feb 11, 2026 CAREY SHEA ROBERTS
Officer
35,532 $3.0M Restricted stock vesting under a registered plan none given none found
Feb 6, 2026 CAFARO DEBRA A
Officer, Director
10,322 $849K Exercise of employee stock options adopted Mar 28, 2024 none found
Feb 2, 2026 CAFARO DEBRA A
Officer, Director
10,322 $802K Exercise of employee stock options adopted Mar 28, 2024 none found
Jan 2, 2026 CAFARO DEBRA A
Officer, Director
10,322 $797K Exercise of employee stock options adopted Mar 28, 2024 none found
Jan 2, 2026 Robert F Probst
Officer
29,930 $2.3M Vested RSU adopted Feb 19, 2025 none found
Dec 1, 2025 CAFARO DEBRA A
Officer, Director
10,322 $831K Exercise of employee stock options adopted Mar 28, 2024 none found
Nov 19, 2025 Bulgarelli Peter J.
Executive Vice President
2,229 $179K Compensation Shares adopted Feb 20, 2025 none found
Nov 18, 2025 Bulgarelli Peter J.
Executive Vice President
2,771 $222K Compensation Shares adopted Feb 20, 2025 none found
Nov 17, 2025 CAFARO DEBRA A
Officer, Director
41,294 $3.3M Exercise of employee stock options adopted Mar 28, 2024 none found
Nov 12, 2025 Robert F Probst
Officer
33,591 $2.6M Exercise of employee stock options adopted Feb 19, 2025 none found
Nov 7, 2025 Bulgarelli Peter J.
Executive Vice President
40 $3K Compensation Shares adopted Feb 20, 2025 none found
Nov 6, 2025 Bulgarelli Peter J.
Executive Vice President
166 $12K Compensation Shares adopted Feb 20, 2025 none found
Nov 6, 2025 CAFARO DEBRA A
Officer, Director
264 $20K Exercise of employee stock options adopted Mar 28, 2024 none found
Nov 5, 2025 Bulgarelli Peter J.
Executive Vice President
870 $65K Compensation Shares adopted Feb 20, 2025 none found
Nov 5, 2025 CAFARO DEBRA A
Officer, Director
19,250 $1.4M Exercise of employee stock options adopted Mar 28, 2024 none found
Nov 4, 2025 Bulgarelli Peter J.
Executive Vice President
3,924 $294K Compensation Shares adopted Feb 20, 2025 none found
Nov 4, 2025 CAFARO DEBRA A
Officer, Director
11,452 $859K Exercise of employee stock options adopted Mar 28, 2024 none found
Nov 3, 2025 CAFARO DEBRA A
Officer, Director
20,644 $1.5M Exercise of employee stock options adopted Mar 28, 2024 none found
Oct 30, 2025 CAFARO DEBRA A
Officer, Director
317,258 $23.6M Exercise of employee stock options adopted Mar 28, 2024 none found
Show the other 13 notices

From the Form 144 XML filed with the SEC, since Oct 30, 2025. The value is the seller's estimate on the notice. "Form 4 sales after" matches the seller's Form 4 sales in the 30 days after the notice, by name; Form 4s go back 180 days.

Next Owners →